Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 5, 1999, Pages 1263-1266

  Voutilainen, Sari ^a   Morrow, Jason D ^b   Roberts II, L Jackson ^b   Alfthan, Georg ^c   Alho, Hannu ^c   Nyyssönen, Kristiina ^a   Salonen, Jukka T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Cardiovascular diseases; F2 isoprostanes; Homocysteine; Lipid peroxidation

Indexed keywords

HOMOCYSTEINE; ISOPROSTANE; LIPID; LOW DENSITY LIPOPROTEIN; PROSTAGLANDIN F2;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENDOTHELIUM INJURY; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032914427     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.5.1263     Document Type: Article

References (29)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274: 1049-1057.
2. Wesch GN, Loscalzo J. Homocysteine and atherosclerosis. N Engl J Med. 1998;338:1042-1050.
3. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339: 883-887.
4. Salonen JT, Nyyssönen K, Salonen R, Porkkala-Sarataho E, Tuomainen T-P, Diczfalusy U, Björkhem I. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation. 1997;95:840-845.
5. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383-9387.
6. Roberts JL II, Morrow JD. The generation and action of isoprostanes. Biochem Biophys Acta. 1991;1345:121-135.
7. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothiombotic disease. Arterioscler Thromb Vasc Biol. 1997; 17:2309-2315.
8. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1997;17: 3236-3241.
9. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997;100:2028-2034.
10. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet. 1997;349:397.
11. Nyyssönen K, Porkkala-Sarataho E, Kaikkonen J, Salonen JT. Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis. 1997;130:223-233.
12. 2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol. 1994;233:163-174.
13. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
14. Salonen JT, Nyyssönen K, Tuomainen T-P, Mäenpää PH, Korpela H, Kaplan GA, Lynch J, Helmrich S, Salonen R. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. Brit Med J. 1995;311: 1124-1127.
15. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res. 1997;36:1-21.
16. Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279-298.
17. Malinow MR, Stampfer MJ. Role of plasma homocyst(e)ine in arterial occlusive diseases. Clin Chem. 1994;40:857-858.
18. Ueland PM, Mansoor MA, Guttormsen AB, Muller F, Aukrust P, Refsum H, Svardal AM. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status: a possible element of the extracellular antioxidant defense system. J Nutr. 1996;126:12818-12848.
19. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upsom B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
20. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.
21. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
22. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
23. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Clarendon Press; 1988.
24. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370-1376.
25. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low-density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res. 1993;2051-2061.
26. Young PB, Kennedy S, Molloy AM, Scott JM, Weir DG, Kennedy DG. Lipid peroxidation induced in vivo by hyperhomocysteinaemia in pigs. Atherosclerosis. 1997;129:67-71.
27. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J. 1997;11:1157-1168.
28. Domagala TB, Libura M, Szczeklik A. Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation. Thromb Res. 1997;87:411-416.
29. Nyyssönen K, Poulsen HE, Hayn M, Agerbo P, Porkkala-Sarataho E, Kaikkonen J, Salonen R, Salonen JT. Effect of supplementation of smoking men with plain or slow release ascorbic acid on lipoprotein oxidation. Eur J Clin Nutr. 1997;51:154-163.